SNRNP35: A Non-Coding RNA Molecule as A Potential Drug Target Or Biomarker

Target Name: SNRNP35

NCBI ID: G11066

SNRNP35

SNRNP35: A Non-Coding RNA Molecule as A Potential Drug Target Or Biomarker

SNRNP35 is a non-coding RNA molecule that has been identified as a potential drug target or biomarker in various diseases, including cancer. SNRNP35 is a key regulator of gene expression in the brain and has been implicated in the development and progression of several neurological disorders.

The SNRNP35 gene has four exons, which encode a protein with 191 amino acid residues. The protein is expressed in various tissues and cells of the body, including the brain, heart, and liver. It is known to play a role in the regulation of gene expression and has been implicated in the development and progression of several neurological disorders, including Alzheimer's disease, Parkinson's disease, and neurodegenerative diseases.

One of the unique features of SNRNP35 is its ability to interact with other non-coding RNAs, including microRNA (miRNA) and long non-coding RNA (lncRNA). These interactions can alter the expression of target genes and are a key mechanism by which SNRNP35 regulates gene expression.

In addition to its role in gene expression, SNRNP35 has also been shown to play a role in the regulation of RNA stability and translation efficiency. Studies have shown that SNRNP35 can interact with the protein stable translocation (STN) complex, which is responsible for regulating the stability and translation of RNA molecules. This interaction between SNRNP35 and STN can alter the stability and translation efficiency of target RNAs and may have implications for the regulation of gene expression.

SNRNP35 has also been shown to play a role in the regulation of cellular processes that are important for brain development and function. For example, studies have shown that SNRNP35 can interact with the protein Calbindin, which is involved in the regulation of stem cell proliferation and differentiation. This interaction between SNRNP35 and Calbindin can influence the expression of genes that are important for brain development and function, including those involved in neurotransmitter synthesis and release.

In conclusion, SNRNP35 is a non-coding RNA molecule that has been identified as a potential drug target or biomarker. Its unique ability to interact with other non-coding RNAs and its role in the regulation of gene expression, RNA stability, and cellular processes important for brain development and function make it an attractive target for further research. Further studies are needed to fully understand the implications of SNRNP35's role in the development and progression of neurological disorders and to develop effective treatments based on this protein.

Protein Name: Small Nuclear Ribonucleoprotein U11/U12 Subunit 35

The "SNRNP35 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNRNP35 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets